If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-22. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
The activation of the endogenous opioids is for an analgesic effect using the gate control theory of pain. In addition, deep dry may also decrease pain, increase range of motion, and minimize myofascial trigger point irritability. In regards to the factor of pain reduction, relief occurs at four central levels: local pain, spinal pain through nerves, brain stem pain, and higher brain center pain. The relief of myofascial trigger points has been more highly researched than the relief of connective tissues, muscle fascia, muscle tension, and scar tissue; however, the American Physical Therapy Association claims that there potentially may be some benefits of dry needling on these ailments according to some available evidence. The APTA also claims that dry needling should not be used as a standalone procedure, but should be used in conjunction with other treatment methods, including manual soft tissue mobilization, neuromuscular re-education, functional retraining, and therapeutic exercises. Once the needle is inserted, one can manually or electrically stimulate the filiform needle depending for the desired effect of treatment.
=== Ruminants === Polioencephalomalacia (PEM) is the most common thiamine deficiency disorder in young ruminant and nonruminant animals. Symptoms of PEM include a profuse, but transient, diarrhea, listlessness, circling movements, stargazing or opisthotonus (head drawn back over neck), and muscle tremors. The most common cause is high-carbohydrate feeds, leading to the overgrowth of thiaminase-producing bacteria, but dietary ingestion of thiaminase (e.g., in bracken fern), or inhibition of thiamine absorption by high sulfur intake are also possible. Another cause of PEM is Clostridium sporogenes or Bacillus aneurinolyticus infection. These bacteria produce thiaminases that can cause an acute thiamine deficiency in the affected animal.
Simon (1973), art dealer and historian who discovered Da Vinci's Salvator Mundi Albie Hecht (1974), founder of Spike TV, head of HLN, and former president of Nickelodeon; creator of Nickelodeon Kids' Choice Awards; Academy Award-nominated producer Alan Goodman (1974), MTV founding executive and Nickelodeon executive Gara LaMarche (1976), former president and CEO of The Atlantic Philanthropies; president of advocacy group Democracy Alliance J. Ezra Merkin (1976), financier, hedge fund manager; former chairman of GMAC Inc. John Slosar (1978), chairman of Swire Pacific and Cathay Pacific airlines Daniel E. Straus (1978), founder of CareOne LLC and former vice chairman of Memphis Grizzlies Jeph Loeb (1979), television writer and EVP of Marvel Television, four-time Eisner Award winner Sami Mnaymneh (1981), billionaire, private equity executive, co-founder of H.I.G. Capital Charles Murphy (1981), hedge fund manager, executive of Fairfield Greenwich Group Tom Glocer (1981), former CEO of Thomson Reuters and Reuters Christopher Radko (1981), businessman and designer, founder of the eponymous Christmas ornaments company Donald F. Ferguson (1982), chief technology officer at Dell and professor of Professional Practice in Computer Science at Columbia University Wayne Allyn Root (1983), business mogul, TV personality and producer, author, 2008 Libertarian Party vice-presidential nominee Daniel S.
Special state certification in the United States is required only in four states: California, Washington, Nevada, and Louisiana. A phlebotomist can become nationally certified through many different organizations. However, California currently only accepts national certificates from six agencies. These include the American Certification Agency (ACA), American Medical Technologists (AMT), American Society for Clinical Pathology (ASCP), National Center for Competency Testing/Multi-skilled Medical Certification Institute (NCCT/MMCI), National Credentialing Agency (NCA), and National Healthcareer Association (NHA). These and other agencies such as the American Society of Phlebotomy Technicians also certify phlebotomists outside the state of California. To qualify to sit for an examination, candidates must complete a full phlebotomy course and provide documentation of clinical or laboratory experience.
Livestock are not usually given opioids due to a stand down period where an animal cannot be used for milking or slaughter following administration and strict regulations that require precise record keeping on administration of opioids.
Sources: en.wikipedia.org
== History == On 5 December 2008, orphan designation (EU/3/08/592) was granted by the European Commission to Medimmune Limited, United Kingdom, for murine anti-CD22 antibody variable region fused to truncated Pseudomonas exotoxin 38 for the treatment of hairy cell leukaemia. It was renamed to Moxetumomab pasudotox. The sponsorship was transferred to AstraZeneca AB, Sweden, in January 2019. On 17 July 2013, orphan designation (EU/3/13/1150) was granted by the European Commission to MedImmune Ltd, United Kingdom, for moxetumomab pasudotox for the treatment of B-lymphoblastic leukaemia / lymphoma. The sponsorship was transferred to AstraZeneca AB, Sweden, in January 2019. Moxetumomab pasudotox was approved for use in the United States in September 2018. The efficacy of moxetumomab pasudotox was studied in a single-arm, open-label clinical trial of 80 subjects who had received prior treatment for hairy cell leukemia with at least two systemic therapies, including a purine nucleoside analog. The trial measured durable complete response (CR), defined as maintenance of hematologic remission for more than 180 days after achievement of CR. Thirty percent of subjects in the trial achieved durable CR, and the overall response rate (number of subjects with partial or complete response to therapy) was 75 percent. The US Food and Drug Administration (FDA) granted the application for moxetumomab pasudotox fast track, priority review, and orphan drug designations. The FDA granted the approval of a Biologics License Application for Lumoxiti to AstraZeneca Pharmaceuticals.
days, which is the time required to reduce the moisture content to 1/e = 37% of its initial deviation from equilibrium. If the relative humidity is 0.50, then using the Hailwood-Horrobin equation the moisture content of the wood at equilibrium is about 7.4%. The time to reduce the lumber from 85% moisture content to 25% moisture content is then about 4.5 days. Higher temperatures will yield faster drying times, but they will also create greater stresses in the wood due because the moisture gradient will be larger. For firewood, this is not an issue but for woodworking purposes, high stresses will cause the wood to crack and be unusable. Normal drying times to obtain minimal seasoning checks (cracks) in 25 mm (1 inch or 4/4 lumber) Red Oak ranges from 22 to 30 days, and in 8/4, (50 mm or 2 inch) it will range from 65 to 90 days.
== Modern reactions == To this day, Jameson's involvement in the Jameson Raid remains something of an enigma, being somewhat out-of-character with his prior history, the rest of his life and successful later political career. In 2002, The Van Riebeeck Society published Sir Graham Bower's Secret History of the Jameson Raid and the South African Crisis, 1895–1902 (edited by Deryck Schreuder and Jeffrey Butler, Van Riebeeck Society, Cape Town, Second Series No. 33), adding to growing historical evidence that the imprisonment and judgement upon the Raiders at the time of their trial was unjust, in view of what has appeared, in later historical analysis, to have been the calculated political manoeuvres by Joseph Chamberlain and his staff to hide his own involvement and knowledge of the Raid. In a 2004 review of Sir Graham Bower's account, Alan Cousins commented that "A number of major themes and concerns emerge" from Bower's history, "perhaps the most poignant being Bower’s accounts of his being made a scapegoat in the aftermath of the raid: 'since a scapegoat was wanted I was willing to serve my country in that capacity'." Cousins writes of Bower that:
Mindfulness is an intentionally focused awareness of one's immediate experience. "Focused awareness" is a conscious moment-by-moment attention to situational elements of an experience: i.e., thoughts, emotions, physical sensations, and surroundings. An aim of mindfulness is to become grounded in the present moment; one learns to observe the arising and passing of experience. One does not judge the experiences and thoughts, nor do they try to "figure things out" and draw conclusions, or change anything – the challenge during mindfulness is to simply observe. Benefits of mindfulness practice include reduction of stress, anxiety, depression, and chronic pain. See also Reverence (emotion). Ellen J. Langer argued people slip into a state of "mindlessness" by engaging in rote behavior, performing familiar, scripted actions without much cognition, as if on autopilot. Advocates of focusing on present experiences also mention research by Psychologist Daniel Gilbert, who suggested daydreaming, instead of a focus on the present, may impede happiness. Fellow researcher, Matt Killingsworth, found evidence to support the harm of daydreaming. Fifteen thousand participants from around the world provided over 650 000 reports (using an online application on their phones that requested data at random times). Killingsworth found people who reported daydreaming soon reported less happiness; daydreaming is extremely common. Zimbardo (see "Time Perspectives" above) bestowed the merits of a present-focus, and recommended occasional recall of past positive experiences.
place the five S American sections, Andinium, Leptidium, Tridens, Rubellium and Chilenium at the base of the phylogenetic tree, in that order. These are followed by the single Australian section, Erpetion, as sister group to Chilenium, the northern hemisphere sections and finally the single African section, V. abyssinica. These sections are morphologically, chromosomally, and geographically distinct.
Sources: en.wikipedia.org
== Signs and symptoms == The symptoms of CMT often appear in childhood and adolescence, but in some cases, they may not develop until adulthood. The severity and progression of symptoms can vary widely between individuals even among members of the same family. Some people do not experience symptoms until their early 30s or 40s. The most common early sign of CMT is difficulty walking, often due to weakness in the muscles of the lower legs and feet. This muscle weakness can lead to foot drop, where patients have trouble lifting the front part of the foot, causing them to trip or adopt a high-stepping gait. Over time, individuals may develop distinctive foot deformities, such as high arches (known as pes cavus) and curled toes (hammertoes), due to muscle imbalance. As the disease progresses, the weakness often spreads to the hands and forearms, making tasks that require fine motor skills—like buttoning a shirt or writing—more difficult. In addition to motor symptoms, many people with CMT also experience a gradual loss of sensation in the feet, legs, hands, and arms. This sensory loss may affect the ability to feel pain, temperature, or touch, and can lead to problems with balance, especially in low-light conditions. Symptoms and progression of the disease can vary. Involuntary grinding of teeth and squinting are prevalent and often go unnoticed by the person affected. Breathing can be affected in some, as can hearing, vision, and neck and shoulder muscles. Scoliosis is common, causing hunching and loss of height. Hip sockets can be malformed.
== Career == After the break-up of the Beat in 1983 (known as the English Beat in North America), vocalists Dave Wakeling and Ranking Roger decided to continue working together in a new venture. They joined up with keyboardist Mickey Billingham (Dexys Midnight Runners), guitarist Mick Jones (the Clash), bassist Horace Panter (the Specials) and drummer Stoker (Dexys Midnight Runners/the Bureau) to form a supergroup of the UK punk and ska scene. They named the band General Public and were rapidly signed to Virgin Records in the UK and I.R.S. Records in North America. The band recorded and released the album All the Rage in 1984. Jones left General Public part way through the recording process, but he is listed in the album's inner sleeve credits as a group member (although he did not appear in any of the band photographs for the album cover). Jones' replacement, guitarist Kevin White, also played on the album and was also listed as an official group member. White's picture also appeared on the album's back cover. In the UK, General Public had a minor hit with the track "General Public", which reached No. 60 in the UK singles chart in 1984. The single's B-side "Dishwasher" (an instrumental mix of "Burning Bright" from All The Rage) became a surprise Top 40 hit in the Netherlands, after its use as a closing theme tune to the pop radio show Avondspits. Later in the year, the band fared even better in North America, where their second single "Tenderness" was a Top 30 hit in Canada (No. 11) and the US (No. 27).
=== Dissolving iron and steel === Alum solution has the property of dissolving steels while not affecting aluminium or base metals. Alum solution can be used to dissolve steel tool bits that have become lodged in machined castings.
=== Anticodon === An anticodon is a unit of three nucleotides corresponding to the three bases of an mRNA codon. Each tRNA has a distinct anticodon triplet sequence that can form 3 complementary base pairs to one or more codons for an amino acid. Some anticodons pair with more than one codon due to wobble base pairing. Frequently, the first nucleotide of the anticodon is one not found on mRNA: inosine, which can hydrogen bond to more than one base in the corresponding codon position. In genetic code, it is common for a single amino acid to be specified by all four third-position possibilities, or at least by both pyrimidines and purines; for example, the amino acid glycine is coded for by the codon sequences GGU, GGC, GGA, and GGG. Other modified nucleotides may also appear at the first anticodon position—sometimes known as the "wobble position"—resulting in subtle changes to the genetic code, as for example in mitochondria. The possibility of wobble bases reduces the number of tRNA types required: instead of 61 types with one for each sense codon of the standard genetic code), only 31 tRNAs are required to translate, unambiguously, all 61 sense codons.
The scientific name Octopoda was first given as the order of octopuses in 1818 by English biologist William Elford Leach, who classified them as Octopoida the previous year. Octopoda consists of around 300 known species and were historically divided into two suborders, the Incirrina and the Cirrina. More recent evidence suggests cirrates are the most basal species, not a unique clade. The incirrate octopuses (the majority of species) lack the cirri and paired swimming fins of the cirrates. In addition, the internal shell of incirrates is either present as a pair of stylets or absent altogether.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.